Introduction {#S5}
============

Combination antiretroviral therapy (cART) increases survival in HIV infected (HIV+) people. Unfortunately, this therapeutic success is associated with an increased prevalence of obesity, the metabolic syndrome, type 2 diabetes (T2D), and cardiovascular disease (CVD), particularly in women ([@R1], [@R2], [@R3]). The adverse metabolic effects of obesity are especially pertinent in the setting of HIV, because HIV+ people already have a 2--4 fold increased risk of developing T2D and CVD than BMI-matched, HIV seronegative (HIV−) people ([@R2], [@R4], [@R5]). Although obesity increases the risk of T2D in people with HIV, increased BMI does not increase the risk of CVD events ([@R6]).

The reason for the high prevalence of T2D in HIV+ people is unclear, but several hypotheses have been proposed. The use of cART, itself, can have adverse metabolic effects, including adipose tissue inflammation ([@R7]), impaired insulin signaling and β-cell dysfunction ([@R8], [@R9]). Furthermore, several protease-inhibitors (PIs) increase endoplasmic reticulum (ER) stress, which can induce inflammation and apoptosis ([@R9], [@R10], [@R11]). The induction of ER stress can also induce autophagy, the orderly degradation and recycling of cellular components. PIs can have adverse effects on autophagy, which could contribute to HIV associated insulin resistance and attenuate the metabolic benefits of weight loss ([@R12], [@R13]).

Moderate (5--10%) weight loss in obese people without HIV infection improves all features of the metabolic syndrome ([@R14], [@R15]). Although weight loss is recommended for obese HIV+ people ([@R16]), it is not known whether weight loss actually confers metabolic benefits in this group. We are aware of only one prospective study that evaluated the effect of weight loss on metabolic outcomes in obese HIV+ patients ([@R17]). In that study, 7% weight loss induced by a low-calorie diet in combination with a supervised exercise program did not result in metabolic benefits. Similarly, Fitch et al were able to reduce waist circumference, but not BMI, using a lifestyle-intervention program however again found no benefit on lipid profile or fasting blood glucose concentration ([@R18]). The reason for the absence of a therapeutic metabolic effect is unclear, but might involve adverse effects of cART, direct effects of HIV on metabolic function, HIV-induced inflammation, and inadequate power to detect a therapeutic effect because of the small number of subjects who had metabolic testing.

The purpose of the present study was to perform a prospective trial to evaluate the effect of moderate 6--8% weight loss, induced by a low-calorie diet, on CVD risk factors, liver and skeletal muscle insulin sensitivity and plasma and adipose tissue markers of inflammation in HIV− and HIV+ women with obesity and who had evidence of insulin-resistant glucose metabolism. We hypothesized that the therapeutic effects of weight loss on insulin sensitivity and markers of inflammation, autophagy and ER stress would be blunted in HIV+ women compared with HIV− women.

Methods {#S6}
=======

Study subjects {#S7}
--------------

Twenty women who were obese and HIV+ (age 37±2 yrs, BMI 43.8±2.9 kg/m^2^, 17 African American, AA, 3 Caucasian) and 8 women who were obese and HIV− (age 40±1 yrs, BMI 39±2 kg/m^2^, 6 AA, 2 Caucasian) enrolled in the study (see [supplemental Figure 1](#SD1){ref-type="supplementary-material"}). All women completed a history and physical examination, standard blood tests, and an oral glucose tolerance test. All participants were "insulin-resistant" based on a homeostasis model assessment of insulin resistance (HOMA-IR) value \> 3.0, impaired fasting glucose or impaired glucose tolerance according to American Diabetes Association criteria ([@R19]) and had ≥2 additional ATP III criteria for metabolic syndrome ([@R20]). Potential participants who consumed an excessive amount of alcohol (\> 2 drinks/day), had a history of hepatitis B or C, or took medications that affect glucose metabolism were excluded. All participants were weight stable (≤2% change in body weight) and sedentary (\<1 hour of exercise per week) for at least two months before beginning the study. All HIV+ women were receiving stable cART, had a plasma CD4+ T-cell count \>200 cells/PL, and an undetectable plasma viral load (\< 50 copies HIV RNA/ml) for at least 6 months before enrollment. The study was approved by the Human Studies Committee of Washington University School of Medicine (St Louis, MO). Written informed consent was obtained from all subjects. The study was registered with clinicaltrials.gov, NCT00857298.

Experimental Design {#S8}
===================

Body composition assessments {#S9}
----------------------------

Body fat and fat-free mass (FFM) were determined by using dual-energy-X-ray absorptiometry ([@R21]). Visceral and abdominal subcutaneous adipose tissue volumes were quantified by using magnetic resonance imaging ([@R22]). Intrahepatic triglyceride content was measured by using magnetic resonance spectroscopy ([@R23]). MRI was not able to be performed in 4 HIV+ subjects and 2 HIV− subjects.

Blood pressure {#S10}
--------------

Systolic and diastolic blood pressures were measured by taking the average of 2 measurements made 5 minutes apart during resting conditions, 30 minutes before the clamp procedure was started.

Hyperinsulinemic-euglycemic-clamp procedure ([Figure 1](#F1){ref-type="fig"} {#S11}
----------------------------------------------------------------------------

All subjects were studied during the follicular phase of their menstrual cycle. A two-stage hyperinsulinemic-euglycemic clamp procedure was performed in conjunction with infusion of \[2,2-^2^H~2~\]-palmitate to assess adipose tissue lipolytic rate, and \[6,6-^2^H~2~\]-glucose to measure endogenous glucose production and glucose disposal rates.

Subjects were admitted to the Clinical Research Unit the day before the clamp procedure. At 1900h, subjects consumed a standard meal, containing 15 kcal·kg·FFM^−1^ and then fasted (except for water) and rested in bed until completion of the clamp procedure the next day. The following morning, at 0500h, a catheter was inserted into an antecubital vein of one arm to infuse insulin, dextrose and stable isotopically-labeled tracers, and another catheter was inserted into a contralateral hand vein, which was placed in a thermostatically controlled (55°C) box to obtain arterialized venous blood samples ([@R24]). At 0600h, a primed (22.5 µmol·kg^−1^), continuous infusion (0.25 µmol·kg^−1^·min^−1^) of \[6,6-^2^H~2~\]glucose was started. At 120 minutes, a continuous infusion (0.035 µmol·kg^−1^·min^−1^) of ^2^H~2~-palmitate was started. At 210 minutes (stage 1), the insulin infusion was initiated at 7 mU·m^2^ body surface area^−1^·min^−1^ (initiated with priming doses of 28 mU·m^2^ body surface area^−1^·min^−1^ for 5 minutes followed by 14 mU·m^2^ body surface area^−1^·min^−1^ for 5 minutes) and continued for 3 hours. At 390 minutes (stage 2), the insulin infusion rate was increased to 50 mU·m^2^ body surface area^−1^·min^−1^ (initiated with priming doses of 200 mU·m^2^ body surface area^−1^·min^−1^ for 5 minutes followed by 100 mU·m^2^ body surface area^−1^·min^−1^ for 5 minutes) and continued for 3.5 hours. Plasma glucose concentration was measured every 10 min during insulin infusion and maintained at \~100 mg/dl by infusing 20% dextrose containing 2.5% \[6,6-^2^H~2~\]glucose. The infusion rate of \[6,6-^2^H~2~\]glucose and \[2,2-^2^H~2~\]palmitate was decreased by 50% during stage 1 and by 75% of the basal rate during stage 2 to account for the expected decline in hepatic glucose production. Blood samples were taken every 10 min during the last 30 minutes of the basal period and stage 1 and stage 2 of the clamp procedure to determine plasma glucose concentration, plasma palmitate and glucose tracer-to-tracee ratios (TTRs), and plasma hormone concentrations. Resting energy expenditure was measured by using indirect calorimetry during the basal period of the clamp procedure (Parvo Medics\' TrueOne® 2400, Sandy, UT) ([@R15]). Adipose tissue biopsies were obtained during the basal stage of the clamp procedure as described previously ([@R25]).

Weight-loss intervention and repeat studies {#S12}
-------------------------------------------

The energy content of the diet was designed to cause a 1000 kcal/day energy deficit based on each subject's estimated energy requirement (calculated as 1.5 × measured resting energy expenditure). Participants received weekly dietary counseling from research dietitians. Meal replacements (Optifast™, Nestle HealthCare Nutrition, Geneva, Switzerland) were provided to replace two meals/day, and subjects were instructed to eat a third meal each day containing regular food. When the targeted 6%--8% weight-loss was achieved, dietary intake was adjusted to maintain a stable body weight for 2 weeks before repeating the body composition assessments, the hyperinsulinemic-euglycemic clamp procedure and abdominal subcutaneous adipose biopsies.

Sample Analyses {#S13}
===============

Plasma substrate and hormone concentrations {#S14}
-------------------------------------------

Plasma glucose concentration was determined by using an automated glucose analyzer (YSI 2300 STAT Plus; Yellow Springs Instrument Co, Yellow Springs, OH). Plasma insulin and leptin concentrations were measured by using a chemiluminescent immunometric method (Immulite; Siemens, Los Angeles, CA). Plasma C-reactive protein (CRP) concentration was measured by using a particle-enhanced immunoturbidometric assay (Roche Diagnostics, IN, USA). HbA1C was measured by using a commercial assay (Roche Diagnostics, IN, USA). Plasma FFA concentrations were quantified by gas chromatography (Hewlett-Packard 5890-II, Palo Alto, CA) ([@R26]).

Plasma glucose and palmitate isotopic enrichment {#S15}
------------------------------------------------

Plasma palmitate and glucose TTRs were measured by using selected ion-monitoring electron impact ionization GC-MS (Hewlett-Packard MSD 5973 system) as previously described ([@R27], [@R28]).

mRNA isolation and quantitative PCR {#S16}
-----------------------------------

Frozen adipose tissue samples were homogenized in TRIzol Reagent (Life Technologies) for total RNA isolation according to the manufacturer\'s protocol. cDNA synthesis was performed (Life Technologies). Quantitative real-time PCR (qRT-PCR) was performed using Power Sybr Green in the ABI 7500 Fast real-time PCR system (Applied Biosystems) to determine mRNA expression levels of the salient genes in adipose tissue samples before and after weight-loss. Primer sequences are provided in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}. qRT-PCR results were analyzed by comparing the sample threshold crossing (*Ct*) after normalization to the housekeeping gene acidic ribosomal phosphoprotein P0 (36B4) (Δ*Ct*). Changes in the threshold crossing (Δ*Ct*) were used to calculate relative levels of each mRNA using the formula 2^−ΔCt^.

Calculations {#S17}
============

Glucose and palmitate rates of appearance (Ra) into plasma and glucose rate of disappearance (Rd) from plasma were calculated as previously described ([@R29]). Insulin sensitivity in: 1) the liver was assessed as the suppression of glucose Ra during low-dose insulin infusion; 2) skeletal muscle was assessed as the increase in glucose Rd during high-dose insulin infusion ; and 3) adipose tissue was assessed as the suppression of palmitate Ra during low-dose insulin infusion ([@R30]).

Statistical Analysis {#S18}
====================

Baseline subject characteristics were compared by using the two-tailed Student's *t*-test. A two-way analysis of variance with repeated measures was used to compare between and within-group differences in the outcome measures induced by weight loss. Tukey's post-hoc procedure was used to locate differences if a significant group × time interaction was found. All P-values ≤ 0.05 were considered statistically significant. Data are expressed as means ± SEM. All data were analyzed by using SPSS (version 18; IBM, New York, USA).

Results {#S19}
=======

Only 19 of the 28 subjects enrolled in the study achieved the targeted 6--8% weight loss and completed the study; 13 HIV+ (10 African-Americans, 3 Caucasians), and 6 HIV− women (4 African-American, 2 Caucasians). Among the HIV+ women initially enrolled, one dropped out due to intolerance of intravenous catheters, one was lost to follow-up and 5 did not meet weight loss goals. Among the HIV− women, 2 were withdrawn because they did not meet weight loss goals. All HIV+ women were treated with emtricitabine and tenofovir and either non-nucleoside reverse-transcriptase inhibitor based therapy (nevirapine (N=3) or efavirenz, (N=4)),or ritonavir-boosted PIs (darunavir (N=2) or atazanavir (N=4)), or raltegravir. The mean duration of known HIV serostatus was 12±2 years (range 4--21 yrs) and the mean duration of cART was 7±1 yrs (range 4--13 yrs). The time to achieve goal weight loss was greater in the HIV+ than the HIV seronegative group (18±2 weeks vs 12±1 weeks, P=0.006). The flow of study subjects is summarized in [supplemental Figure 1](#SD1){ref-type="supplementary-material"}.

Body composition {#S20}
----------------

Baseline body composition and fat distribution were not different between the HIV− and HIV+ groups ([Table 1](#T1){ref-type="table"}). Mean weight loss was not different between the HIV− and HIV+ subjects (−7.3±0.1% vs −7.7±0.1%, respectively), and caused a similar reduction in visceral adipose tissue volume and intrahepatic triglyceride (IHTG) content in both groups ([Table 1](#T1){ref-type="table"}). In contrast, weight loss caused a greater decrease in both whole body and appendicular (limb) fat-free mass in HIV+ than HIV− subjects ([Table 1](#T1){ref-type="table"}).

Metabolic variables {#S21}
-------------------

Weight loss decreased systolic and diastolic blood pressures (P \< 0.05) and tended to decrease fasting blood glucose concentration (P=0.08) in both groups, without any differences between groups ([Table 1](#T1){ref-type="table"}). Fasting plasma insulin and C-peptide concentrations were not different between groups at baseline, and were lower after weight loss in the HIV− (P \< 0.01), but not the HIV+ group. Accordingly, the percent change in fasting plasma insulin concentration was greater in the HIV− than the HIV+ group (P \< 0.03).

By design, plasma glucose concentrations during the high-dose insulin infusion of the euglycemic-hyperinsulinemic clamp procedure were the same before and after weight loss in the HIV− (101.1±0.7 and 101.7±1.7 mg/dl) and HIV+ (101.0±1.0 and 101.9±1.1 mg/dl) groups, and were not different between groups. Plasma insulin concentrations during the clamp procedure were also the same before and after weight loss in both HIV− (81.0±4.3 and 86.1±9.3 µU/ml) and HIV+ (74.6±4.6 and 74.6±5.6 µU/ml) groups.

At baseline, basal glucose Ra, glucose Rd and palmitate Ra and the effect of insulin infusion on glucose and palmitate kinetics were not different between HIV− and HIV+ subjects ([Figure 1](#F1){ref-type="fig"}). Both the absolute and relative decreases in palmitate Ra during stage 1 of the clamp procedure were greater after weight loss than before weight loss in both groups, without a difference between groups ([Figure 1](#F1){ref-type="fig"}). Weight loss did not affect basal glucose Ra, but tended to cause a greater decline in glucose Ra during low-dose insulin infusion in both groups, but the decreases were not statistically significant ([Figure 1](#F1){ref-type="fig"}). Both the absolute and relative increase in glucose Rd during insulin infusion were greater after weight loss than before weight loss in both groups, without a difference between groups ([Figure 1](#F1){ref-type="fig"}).

Plasma immune and inflammatory markers {#S22}
--------------------------------------

At baseline, mean plasma CRP concentration was not different between groups, and tended to decrease after weight loss in both HIV− (from 5.9±1.9 to 4.4±1.5 mg/L) and HIV+ (from 5.2±1.3 to 4.2±1.0 mg/L) subjects, but the changes were not statistically significant (P=0.14). Plasma HIV viremia was undetectable in HIV+ subjects at baseline and remained undetectable after weight loss. In addition, weight loss did not affect CD4+ T-cell counts (641±79 cells/µL before and 701±81 cells/µL after weight loss, P=0.29).

Adipose tissue biology {#S23}
----------------------

Gene expression of markers of inflammation (ITGAM, EMR1, TNFα, MCP1, IL-6, ITGAX, MRC2) ([Figure 2A](#F2){ref-type="fig"}), ER stress (sXBP1, XPB1, CHOP and Grp78) ([Figure 2B](#F2){ref-type="fig"}) or autophagy (ATF4, C/EBP, FOXO3, P53, P73, Lamp2, ULK1, TFEB, LAL, ATG7, BNIP) ([Figure 2C](#F2){ref-type="fig"}) were not different between groups at baseline (data not shown) and did not change with weight loss in either HIV− or HIV+ groups..

Discussion {#S24}
==========

The results from this study provide the first evidence that moderate diet-induced weight loss improves metabolic function in insulin-resistant, HIV+ women who are obese. Matched weight loss caused a similar improvement in multi-organ insulin sensitivity, decline in intra-abdominal adipose tissue volume and IHTG content, and decreased systolic and diastolic blood pressure in both groups. These cardiometabolic improvements were not associated with alterations in adipose tissue gene expression of markers of inflammation, autophagy or ER stress. In contrast, weight loss caused a greater decrease in FFM in HIV+ than in HIV− women. These results demonstrate that moderate diet-induced weight loss has important therapeutic cardiometabolic effects in HIV+ women with obesity.

Our finding that moderate (\~7%) weight loss improves skeletal muscle insulin sensitivity, assessed as insulin-mediated glucose disposal rate during insulin infusion, differ from the results of a previous study that found a 7% weight loss achieved by dietary modification and physical activity failed to improve insulin sensitivity, assessed by using the frequently-sampled intravenous glucose tolerance test ([@R17]). The results from two other studies found that lifestyle therapy in patients with HIV infection resulted in a decrease in waist circumference without a change in body weight, but failed to show any beneficial metabolic benefits ([@R18], [@R31]). The reason for the different findings between our study and the previous study that found weight loss in HIV+ patients did not improve insulin sensitivity could be related to differences in cART regimens and in the methods used to assess insulin action. Our patients received ritonavirboosted darunavir or atazanavir and emtricitabine with tenofovir, which could have less adverse metabolic effects than older (unspecified) PIs used in the previous study ([@R32], [@R33], [@R34]). In addition, we assessed insulin sensitivity by using a two-stage hyperinsulinemic-euglycemic clamp procedure in conjunction with a stable isotopically labeled glucose tracer infusion, which is a more sensitive measure of insulin action than the frequently-sampled intravenous glucose tolerance test ([@R35]). Nonetheless, despite the improvement we observed in insulin sensitivity, the decline in basal plasma insulin concentration was blunted in HIV+ compared with HIV− subjects. The absence of a decline in plasma insulin concentrations after weight loss in obese HIV-infected people has been reported previously ([@R17]). The reason for persistent basal hyperinsulinemia is not known.

Data from studies conducted in rodent models and in human subjects suggest that ER stress and unfolded protein response-pathways are increased in the setting of obesity and hyperinsulinemia and could be involved in the pathogenesis of insulin resistance ([@R36], [@R37]). However our data do not support the notion that decreased adipose tissue inflammation, autophagy or ER stress are responsible for the weight loss-induced improvement in cardiometabolic outcomes. Adipose tissue markers of these biological processes did not change after weight loss in either HIV− or HIV+ subjects. Our results are consistent with data from previous clinical studies demonstrating that moderate weight loss does not affect markers of inflammation in adipose tissue ([@R38]), and we are not aware of any studies that evaluated the effect of moderate weight loss on autophagy or ER stress. However, marked (\~30%) weight loss reduces markers of ER stress ([@R39]),

Diet induced weight loss caused a greater decrease in whole-body and appendicular FFM in HIV+ women than HIV− women. The mechanism responsible for the difference in FFM loss between groups is not known, but could be due to insulin-resistant protein metabolism in skeletal muscle, in conjunction with the catabolic effects of a hypocaloric diet. We previously found that whole-body proteolytic rates are increased and insulin-mediated suppression of muscle protein breakdown is impaired in insulin resistant HIV+ people ([@R40]). It is unlikely that differences in protein intake between groups confounded our findings because subjects received at least 42 grams (\~0.75g/kgFFM/day) of protein from liquid shakes (Optifast™, Nestle Health Care Nutrition, Geneva, Switzerland) in addition to the dietary protein in their main meals each day. Nonetheless, it is unlikely the small (\~1.3 kg) greater decline in FFM in HIV+ subjects had adverse effects on physical function.

Our study has several limitations. First, we only included women, so our findings might not apply to men. However, obesity is approximately three times more common in HIV+ women than HIV+ men, so our results are relevant to a large proportion of people with HIV infection. Nonetheless, future studies conducted in men will be needed to confirm whether the results we found in women are also found in men. Second, our subjects were being treated with several different antiretroviral regimens; therefore we cannot determine whether specific cART regimens influence the metabolic benefits of weight loss. Third, the number of subjects in each group was small, which decreased our ability to detect differences between the groups. However, we used precise and reproducible measures of metabolic function ([@R35]), and found the differences in key outcome measures between groups were very small making it unlikely we missed physiologically-important differences. Finally, although we did not find differences between groups in either adipose tissue or systemic markers of inflammation, our assessment of systemic inflammation (plasma CRP concentration) was not robust, so it is possible that additional and more sensitive markers (e.g. soluble CD14, CD163, MIP-1a) could have detected an effect of HIV infection and weight loss.

In summary, moderate weight loss improved multi-organ insulin sensitivity and several other key risk factors for cardiovascular disease in women with obesity and HIV-infection to the same degree that weight loss improved these outcome measures in women with obesity but without HIV-infection. However, weight loss in HIV+ women caused a greater decline in FFM than the same amount of weight loss in HIV− women.
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![Percent suppression of palmitate Ra and glucose Ra during stage 1 of the hyperinsulinemic-euglycemic clamp procedure and percent stimulation of glucose Rd during stage 2 of the hyperinsulinemic-euglycemic clamp procedure before and after weight loss in HIV− (black bars) and HIV+ subjects (grey bars). \* Main effect of time, P \< 0.05](nihms844993f1){#F1}

![Fold-changes in adipose tissue gene expression of markers of inflammation (A), autophagy (B), and endoplasmic reticulum stress (C) after weight loss in HIV -- (black bars) and HIV+ subjects (grey bars)\
ITGAM, integrin α-M (CD11b); EMR1, EGR-like module-containing mucin-like hormone receptor-1 like 1; TNFα, tumor necrosis factor α; MCP1, monocyte chemoattractant protein 1, IL-6, interleukin 6; MRC2, mannose-receptor 2; ITGAX, integrin alpha X (CD11c). mRNA expression normalized to the housekeeping control gene acidic ribosomal phosphoprotein P0 (36B4); ATF4, activating transcription factor 4; CEBP, CCAAT enhancer-binding protein; FOXO3, forkhead box O3; lysosomal-associated membrane protein 2; ULK-1, unc-51 like autophagy activating kinase; TFEB, transcription factor EB; LAL, lysosomal acid phosphatase; ATG7, autophagy-related protein 7; BNIP BCL2/adenovirus E1B protein-interacting protein. mRNA expression normalized to the housekeeping control gene acidic ribosomal phosphoprotein P0 (36B4); sXBP1, spliced x-box binding protein 1; XBP1, x-box binding protein 1; CHOP, C/EBP homologous protein; Grp78, glucose-regulated protein 78.](nihms844993f2){#F2}

###### 

Body composition and cardiometabolic variables before and after weight loss.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                HIV− before                               HIV− after                                                                 Percent\                                     HIV+\                                     HIV+ after                                                                  Percent\
                                                                                                                                                     difference                                   before                                                                                                                difference
  ----------------------------- ----------------------------------------- -------------------------------------------------------------------------- -------------------------------------------- ----------------------------------------- --------------------------------------------------------------------------- --------------------------------------------
  Body weight (kg)              113±17                                    105±6                                                                      −7.3±0.1[\*](#TFN3){ref-type="table-fn"}     108±5                                     100±4                                                                       −7.7±0.1[\*](#TFN3){ref-type="table-fn"}

  BMI (kg/m^2^)                 39.9±2.2                                  36.9±1.9                                                                   −7.1±1.0[\*](#TFN3){ref-type="table-fn"}     39.1±1.6                                  36.3±1.5                                                                    −7.2±0.8[\*](#TFN3){ref-type="table-fn"}

  Fat-free mass (kg)            55.7±3.0[B](#TFN5){ref-type="table-fn"}   54.8±2.9[A](#TFN4){ref-type="table-fn"}, [B](#TFN5){ref-type="table-fn"}   −1.7±1.0[B](#TFN5){ref-type="table-fn"}      51.1±2.0[B](#TFN5){ref-type="table-fn"}   48.9±1.9[A](#TFN4){ref-type="table-fn"}, [B](#TFN5){ref-type="table-fn"}    −4.4±0.7[B](#TFN5){ref-type="table-fn"}

  Appendicular fat-free mass\   25.5±.9                                   25.4±1.1[\*](#TFN3){ref-type="table-fn"}                                   −0.6±2.4                                     25.2±1.3                                  23.7±1.1[\*](#TFN3){ref-type="table-fn"}, [B](#TFN5){ref-type="table-fn"}   −5.8±0.7[B](#TFN5){ref-type="table-fn"}
  (kg)                                                                                                                                                                                                                                                                                                                  

  Fat mass (% body weight)      45.9±2.4                                  44.0±2.3                                                                   −4.4±1.6[\*](#TFN3){ref-type="table-fn"}     49.7±1.6                                  48.0±1.4                                                                    −3.2±0.8[\*](#TFN3){ref-type="table-fn"}

  Total abdominal adipose\      5052±574                                  4815±618                                                                   −6.4±4.9[\*](#TFN3){ref-type="table-fn"}     5227±428                                  4757±461[\*](#TFN3){ref-type="table-fn"}                                    −7.4±3.1[\*](#TFN3){ref-type="table-fn"}
  tissue (cm^3^)                                                                                                                                                                                                                                                                                                        

  Visceral adipose tissue\      1139±187                                  1034±183                                                                   −12±4[\*](#TFN3){ref-type="table-fn"}        1164±140                                  997±137[\*](#TFN3){ref-type="table-fn"}                                     −14±4[\*](#TFN3){ref-type="table-fn"}
  (cm^3^)                                                                                                                                                                                                                                                                                                               

  VAT:TAT ratio                 0.22±0.03                                 0.22±0.03                                                                  −5.1±4.7[\*](#TFN3){ref-type="table-fn"}     0.24±0.03                                 0.22±0.03[\*](#TFN3){ref-type="table-fn"}                                   −7.1±3.0[\*](#TFN3){ref-type="table-fn"}

  IHTG content (%)              7.5±2.4                                   5.4±1.5                                                                    −16.8±43.8[\*](#TFN3){ref-type="table-fn"}   4.6±1.7                                   2.2±1.0[\*](#TFN3){ref-type="table-fn"}                                     −26.3±18.6[\*](#TFN3){ref-type="table-fn"}

  Systolic BP (mmHg)            126±5                                     117±6                                                                      −7±4[\*](#TFN3){ref-type="table-fn"}         122±3                                     118±4                                                                       −4±2[\*](#TFN3){ref-type="table-fn"}

  Diastolic BP (mmHg)           76±5                                      69±5                                                                       −9±3[\*](#TFN3){ref-type="table-fn"}         72±3                                      69±3                                                                        −4±3[\*](#TFN3){ref-type="table-fn"}

  Glucose (mg/dl)               91.5±3.0                                  87.6±2.5                                                                   −4.0±3.3                                     94.1±2.0                                  91.7±1.6                                                                    −2.2±2.0

  Insulin (µU/L)                18.3±3.3                                  8.8±2.6 [A](#TFN4){ref-type="table-fn"}, [B](#TFN5){ref-type="table-fn"}   −54.0±7.3[B](#TFN5){ref-type="table-fn"}     16.6±2.5                                  14.2±1.9[B](#TFN5){ref-type="table-fn"}                                     −11.1±10.5[B](#TFN5){ref-type="table-fn"}

  C-peptide (ng/ml)             3.2±0.5                                   2.2±0.4[A](#TFN4){ref-type="table-fn"}, [B](#TFN5){ref-type="table-fn"}    −28.2±9.4                                    2.8±0.3                                   2.7±0.2[B](#TFN5){ref-type="table-fn"}                                      −3.9±6.6[B](#TFN5){ref-type="table-fn"}

  Leptin (µg/L)                 39.0±6.6                                  36.2±6.3                                                                   −8.6±11.8[\*](#TFN3){ref-type="table-fn"}    53.1±4.5                                  39.8±4.3                                                                    −20.4±6.4[\*](#TFN3){ref-type="table-fn"}

  Hemoglobin A1C (%)            5.8±0.2                                   5.3±0.2                                                                    −7.9±2.9                                     5.7±0.1                                   5.6±0.1                                                                     −3.2±2.0

  FFA (µmol/ml)                 550±66                                    527±85                                                                     −3.1±7.9                                     661±45                                    662±58                                                                      −1.1±8.4

  LDL-C (mg/dl)                 111±14                                    100±7                                                                      −9±5                                         103±10                                    101±12                                                                      −1±4

  HDL-C (mg/dl)                 43±3                                      39±3[A](#TFN4){ref-type="table-fn"}                                        −9±3[\*](#TFN3){ref-type="table-fn"}         42±2                                      39±2 [A](#TFN4){ref-type="table-fn"}                                        −7±3[\*](#TFN3){ref-type="table-fn"}

  Triglyceride (mg/dl)          128±28                                    92±28                                                                      −17±15                                       112±18                                    119±22                                                                      12±12
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Values are means±SE.

VAT:TAT, visceral adipose tissue (VAT) area as percent total abdominal adipose tissue (TAT) area; IHTG, intrahepatic triglyceride content; FFA, free-fatty acid; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.

P\<0.05 for main effect of time.

Value is different from corresponding value at baseline, P\<0.05.

Value is different from corresponding value in other group, P\<.0.05.

What is known {#S26}
=============

-   Obesity is extremely common in women with HIV infection, and is associated with insulin resistance, dyslipidemia and cardiovascular disease.

-   HIV infection and its treatment are associated with a markedly increased risk of diabetes and cardiovascular disease, possibly due to adipose-tissue inflammation and/or ER stress.

-   Prior studies have found that women with HIV infection and obesity have blunted improvements in insulin-sensitivity and other cardiovascular risk factors when they undergo moderate weight-loss compared to HIV-seronegative women.

What this study adds {#S27}
====================

-   Moderate weight-loss caused similar improvements in insulin sensitivity, between the HIV seropositive and seronegative groups.

-   Despite similar amounts of weight loss, women with HIV infection lost significantly more fat-free mass and appendicular fat-free mass than HIV seronegative women.

-   Weight-loss did not reduce markers of inflammation or ER stress in adipose tissue in either seropositive and seronegative groups.
